BACKGROUND: The most effective highly active antiretroviral therapy (HAART) to prevent mother-to-child transmission of human immunodeficiency virus type 1 (HIV-1) in pregnancy and its efficacy during breast-feeding are unknown. METHODS: We randomly assigned 560 HIV-1-infected pregnant women (CD4+ count, > or = 200 cells per cubic millimeter) to receivecoformulated abacavir, zidovudine, and lamivudine (the nucleoside reverse-transcriptase inhibitor [NRTI] group) or lopinavir-ritonavir plus zidovudine-lamivudine (the protease-inhibitor group) from 26 to 34 weeks' gestation through planned weaning by 6 months post partum. A total of 170 women with CD4+ counts of less than 200 cells per cubic millimeter receivednevirapine plus zidovudine-lamivudine (the observational group). Infants received single-dose nevirapine and 4 weeks of zidovudine. RESULTS: The rate of virologic suppression to less than 400 copies per milliliter was high and did not differ significantly among the three groups at delivery (96% in the NRTI group, 93% in the protease-inhibitor group, and 94% in the observational group) or throughout the breast-feeding period (92% in the NRTI group, 93% in the protease-inhibitor group, and 95% in the observational group). By 6 months of age, 8 of 709 live-born infants (1.1%) were infected (95% confidence interval [CI], 0.5 to 2.2): 6 were infected in utero (4 in the NRTI group, 1 in the protease-inhibitor group, and 1 in the observational group), and 2 were infected during the breast-feeding period (in the NRTI group). Treatment-limiting adverse events occurred in 2% of women in the NRTI group, 2% of women in the protease-inhibitor group, and 11% of women in the observational group. CONCLUSIONS: All regimens of HAART from pregnancy through 6 months post partum resulted in high rates of virologic suppression, with an overall rate of mother-to-child transmission of 1.1%. (ClinicalTrials.gov number, NCT00270296.) 2010 Massachusetts Medical Society
RCT Entities:
BACKGROUND: The most effective highly active antiretroviral therapy (HAART) to prevent mother-to-child transmission of humanimmunodeficiency virus type 1 (HIV-1) in pregnancy and its efficacy during breast-feeding are unknown. METHODS: We randomly assigned 560 HIV-1-infected pregnant women (CD4+ count, > or = 200 cells per cubic millimeter) to receive coformulated abacavir, zidovudine, and lamivudine (the nucleoside reverse-transcriptase inhibitor [NRTI] group) or lopinavir-ritonavir plus zidovudine-lamivudine (the protease-inhibitor group) from 26 to 34 weeks' gestation through planned weaning by 6 months post partum. A total of 170 women with CD4+ counts of less than 200 cells per cubic millimeter received nevirapine plus zidovudine-lamivudine (the observational group). Infants received single-dose nevirapine and 4 weeks of zidovudine. RESULTS: The rate of virologic suppression to less than 400 copies per milliliter was high and did not differ significantly among the three groups at delivery (96% in the NRTI group, 93% in the protease-inhibitor group, and 94% in the observational group) or throughout the breast-feeding period (92% in the NRTI group, 93% in the protease-inhibitor group, and 95% in the observational group). By 6 months of age, 8 of 709 live-born infants (1.1%) were infected (95% confidence interval [CI], 0.5 to 2.2): 6 were infected in utero (4 in the NRTI group, 1 in the protease-inhibitor group, and 1 in the observational group), and 2 were infected during the breast-feeding period (in the NRTI group). Treatment-limiting adverse events occurred in 2% of women in the NRTI group, 2% of women in the protease-inhibitor group, and 11% of women in the observational group. CONCLUSIONS: All regimens of HAART from pregnancy through 6 months post partum resulted in high rates of virologic suppression, with an overall rate of mother-to-child transmission of 1.1%. (ClinicalTrials.gov number, NCT00270296.) 2010 Massachusetts Medical Society
Authors: Alice M Stek; Mark Mirochnick; Edmund Capparelli; Brookie M Best; Chengcheng Hu; Sandra K Burchett; Carol Elgie; Diane T Holland; Elizabeth Smith; Ruth Tuomala; Amanda Cotter; Jennifer S Read Journal: AIDS Date: 2006-10-03 Impact factor: 4.177
Authors: Ibou Thior; Shahin Lockman; Laura M Smeaton; Roger L Shapiro; Carolyn Wester; S Jody Heymann; Peter B Gilbert; Lisa Stevens; Trevor Peter; Soyeon Kim; Erik van Widenfelt; Claire Moffat; Patrick Ndase; Peter Arimi; Poloko Kebaabetswe; Patson Mazonde; Joseph Makhema; Kenneth McIntosh; Vladimir Novitsky; Tun-Hou Lee; Richard Marlink; Stephen Lagakos; Max Essex Journal: JAMA Date: 2006-08-16 Impact factor: 56.272
Authors: Roy M Gulick; Heather J Ribaudo; Cecilia M Shikuma; Stephanie Lustgarten; Kathleen E Squires; William A Meyer; Edward P Acosta; Bruce R Schackman; Christopher D Pilcher; Robert L Murphy; William E Maher; Mallory D Witt; Richard C Reichman; Sally Snyder; Karin L Klingman; Daniel R Kuritzkes Journal: N Engl J Med Date: 2004-04-29 Impact factor: 91.245
Authors: Asda Vibhagool; Pedro Cahn; Mauro Schechter; Fiona Smaill; Luis Soto-Ramirez; Giampiero Carosi; Maria Montroni; Cristina E Pharo; Jamie C Jordan; Nicola E Thomas; Gill Pearce Journal: Curr Med Res Opin Date: 2004-07 Impact factor: 2.580
Authors: Ruth E Tuomala; David E Shapiro; Lynne M Mofenson; Yvonne Bryson; Mary Culnane; Michael D Hughes; M J O'Sullivan; Gwendolyn Scott; Alice M Stek; Diane Wara; Marc Bulterys Journal: N Engl J Med Date: 2002-06-13 Impact factor: 91.245
Authors: Pamela K Kohler; Kenneth Ondenge; Lisa A Mills; John Okanda; John Kinuthia; George Olilo; Frank Odhiambo; Kayla F Laserson; Brenda Zierler; Joachim Voss; Grace John-Stewart Journal: AIDS Patient Care STDS Date: 2014-12 Impact factor: 5.078
Authors: Denise J Jamieson; Charles S Chasela; Michael G Hudgens; Caroline C King; Athena P Kourtis; Dumbani Kayira; Mina C Hosseinipour; Deborah D Kamwendo; Sascha R Ellington; Jeffrey B Wiener; Susan A Fiscus; Gerald Tegha; Innocent A Mofolo; Dorothy S Sichali; Linda S Adair; Rodney J Knight; Francis Martinson; Zebrone Kacheche; Alice Soko; Irving Hoffman; Charles van der Horst Journal: Lancet Date: 2012-04-26 Impact factor: 79.321
Authors: Veronica Escamilla; Carla J Chibwesha; Matthew Gartland; Namwinga Chintu; Mwangelwa Mubiana-Mbewe; Kebby Musokotwane; Patrick Musonda; William C Miller; Jeffrey S A Stringer; Benjamin H Chi Journal: J Acquir Immune Defic Syndr Date: 2015-11-01 Impact factor: 3.731
Authors: Matthew G Gartland; Namwinga T Chintu; Michelle S Li; Mwila K Lembalemba; Saziso N Mulenga; Maximillian Bweupe; Patrick Musonda; Elizabeth M Stringer; Jeffrey S A Stringer; Benjamin H Chi Journal: AIDS Date: 2013-05-15 Impact factor: 4.177
Authors: Nicole L Davis; William C Miller; Michael G Hudgens; Charles S Chasela; Dorothy Sichali; Dumbani Kayira; Julie A E Nelson; Jeffrey S A Stringer; Sascha R Ellington; Athena P Kourtis; Denise J Jamieson; Charles van der Horst Journal: AIDS Date: 2014-11-28 Impact factor: 4.177
Authors: Henrik N Kløverpris; Reuben McGregor; James E McLaren; Kristin Ladell; Mikkel Harndahl; Anette Stryhn; Jonathan M Carlson; Catherine Koofhethile; Bram Gerritsen; Can Keşmir; Fabian Chen; Lynn Riddell; Graz Luzzi; Alasdair Leslie; Bruce D Walker; Thumbi Ndung'u; Søren Buus; David A Price; Philip J Goulder Journal: J Immunol Date: 2015-04-24 Impact factor: 5.422
Authors: Sumona Chaudhury; Gloria K Mayondi; Paige L Williams; Jean Leidner; Roger Shapiro; Modiegi Diseko; Gbolahan Ajibola; Penny Holding; Vicki Tepper; Joseph Makhema; Chipo Petlo; George R Seage; Shahin Lockman; Betsy Kammerer Journal: AIDS Date: 2018-06-01 Impact factor: 4.177
Authors: Scott Dryden-Peterson; Memory Bvochora-Nsingo; Gita Suneja; Jason A Efstathiou; Surbhi Grover; Sebathu Chiyapo; Doreen Ramogola-Masire; Malebogo Kebabonye-Pusoentsi; Rebecca Clayman; Abigail C Mapes; Neo Tapela; Aida Asmelash; Heluf Medhin; Akila N Viswanathan; Anthony H Russell; Lilie L Lin; Mukendi K A Kayembe; Mompati Mmalane; Thomas C Randall; Bruce Chabner; Shahin Lockman Journal: J Clin Oncol Date: 2016-11-01 Impact factor: 44.544